Physician profile
Bonnie Lynn Hill
NPI 1538585385
$371,834.49
in general payments reported to CMS, 2019-2025
22 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60K · 2022: $47K · 2023: $68K · 2024: $89K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $191K · Travel and Lodging: $42K · Consulting Fee: $19K · Food and Beverage: $12K · Honoraria: $173 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $191,215.00 |
| Travel and Lodging | $42,466.94 |
| Consulting Fee | $18,577.50 |
| Food and Beverage | $12,314.26 |
| Honoraria | $172.50 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $281,271.84 | 2021-2025 | |
| Madrigal Pharmaceuticals | $26,740.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $23,347.64 | 2021-2024 | Epclusa |
| Evoke Pharma, INC. | $17,063.88 | 2023-2025 | Gimoti |
| Aimmune Therapeutics, INC. | $13,919.07 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $5,365.29 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,150.95 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $611.26 | 2021-2025 | Tremfya, Stelara, Xarelto |
| Redhill Biopharma INC. | $320.78 | 2021-2024 | Talicia |
| Novo Nordisk INC | $186.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $176.68 | 2021-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $176.27 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $82.36 | 2022-2025 | Dupixent |
| Celgene Corporation | $82.23 | 2022-2023 | Zeposia |
| Genzyme Corporation | $78.99 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $71.09 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $61.16 | 2023-2025 | Mounjaro, Omvoh |
| Merck Sharp & Dohme LLC | $35.56 | 2022-2023 | Dificid |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.19 | 2022 | |
| Qol Medical, LLC | $28.97 | 2021 | |
| Celltrion USA INC. | $16.91 | 2025 | Vegzelma |
| Enterra Medical, INC. | $15.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.